Project description
Addressing neurocysticercosis in sub-Saharan Africa
Neurocysticercosis (NCC) is a fatal disease caused by the ingestion of pork tapeworm eggs. It is prevalent in sub-Saharan Africa and can cause severe damage to the central nervous system, with epileptic seizures as the primary symptom. NCC management guidelines have been published by the WHO, but their uptake in national policies is limited. The EU-funded NeuroSolve project will investigate the implementation of a combination treatment against parasitic infections and a serological test. The project will provide training to early-career researchers and healthcare workers, upgrade surveillance infrastructure, demonstrate the effectiveness of combined treatments, and evaluate the impact of serological testing and the cost-effectiveness of the proposed health technologies. Policy-makers and relevant stakeholders will be involved throughout the project, facilitating the translation of research outcomes into policy.
Objective
Neurocysticercosis (NCC) is a fatal zoonotic disease following ingestion of eggs of the pork tapeworm, Taenia solium. The eggs develop to larval forms (cysticerci) in various tissues, including those of the central nervous system, leading to NCC, mainly characterized by epileptic seizures. NCC management guidelines have been published by the WHO, however, their uptake in national policies is very limited. In NeuroSolve, we will demonstrate and promote a methodological approach for conducting health research that leads to improved adoption into policy and clinical practise. We will validate the approach by investigating evaluation- and implementation of an antiparasitic combination treatment and a serological test. Two health innovations that can make a major positive contribution to NCC management. The proposed approach includes (1) strengthening of clinical and research capacity through training and mentoring of early career researchers, clinicians and frontline healthcare workers as well as upgrading infrastructure for surveillance and control, (2) demonstrating the improved pragmatic effectiveness of the combined treatment on quality of life (3) evaluating the potential impact of serological testing on the patient outcomes and the wider health system through a simulation study, (4) demonstrating the cost-effectiveness and cost-benefit of the proposed health technologies, (5) developing and validating an implementation strategy that addresses identified barriers for uptake using the robust implementation frameworks and 6) enhance research results uptake into national and international guidelines and health policy through engagement of relevant policy makers throughout the project period and beyond. If the intended impacts are reached, NeuroSolve will improve health outcomes of NCC patients, provide a blueprint for meaningful implementation research and demonstrate to policy makers how research can strengthen healthcare systems.
Fields of science
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
Funding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
73024 MAGLIE
Italy